InsidersTradesSigma
Follow the Silo Pharma, Inc. stock price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Silo Pharma, Inc. has recorded 24 public disclosures. Market capitalisation: €5.5m. The latest transaction was filed on 16 December 2025 (Acquisition). Among the most active insiders: Weisblum Eric. Every trade is openly available.
24
Insider Decl.
n/a
Thresholds
€41,621
23 ops.
Buy Volume
n/a
n/a
Sell Volume
59Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,757 of 29,064 companies
15.1
score / 100
Value1
Quality29
FCF yld-124%
Earn yld-100%
EV/EBITDA·
ROE-100%
Gross mgn39%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 16 December 2025
Declarations24 total
2,500 shares@ US$0.412.4% of flowCommon StockSEC:0001213900-25-122429:0
Canonical exit: 15 Mar 2026 (T+90)
1,000 shares@ US$0.370.9% of flowCommon StockSEC:0001213900-25-113743:0
Canonical exit: 18 Feb 2026 (T+90)
7,500 shares@ US$0.40337.5% of flowCommon StockSEC:0001213900-25-113104:0
Canonical exit: 16 Feb 2026 (T+90)
10,000 shares@ US$0.43299.6% of flowCommon StockSEC:0001213900-25-048304:0
Canonical exit: 25 Aug 2025 (T+90)
2,500 shares@ US$0.83876.1% of flowCommon StockSEC:0001213900-24-109363:0
Canonical exit: 13 Mar 2025 (T+90)
2,500 shares@ US$0.956.8% of flowCommon StockSEC:0001213900-24-101610:0
Canonical exit: 18 Feb 2025 (T+90)
562 shares@ US$1.081.7% of flowCommon StockSEC:0001213900-24-052354:0
Canonical exit: 9 Sept 2024 (T+90)
600 shares@ US$1.963.3% of flowCommon StockSEC:0001213900-24-031159:0
Canonical exit: 3 Jul 2024 (T+90)
3,408 shares@ US$1.9418.6% of flowCommon StockSEC:0001213900-24-028973:0
Canonical exit: 26 Jun 2024 (T+90)
500 shares@ US$1.632.3% of flowCommon StockSEC:0001213900-23-097689:0
Canonical exit: 18 Mar 2024 (T+90)
200 shares@ US$1.500.8% of flowCommon StockSEC:0001213900-23-096606:0
Canonical exit: 13 Mar 2024 (T+90)
600 shares@ US$1.392.3% of flowCommon StockSEC:0001213900-23-094145:0
Canonical exit: 4 Mar 2024 (T+90)
1,000 shares@ US$1.574.3% of flowCommon StockSEC:0001213900-23-091665:0
Canonical exit: 27 Feb 2024 (T+90)
400 shares@ US$1.681.9% of flowCommon StockSEC:0001213900-23-090270:0
Canonical exit: 20 Feb 2024 (T+90)
4,050 shares@ US$1.6018.1% of flowCommon StockSEC:0001213900-23-089570:0
Canonical exit: 18 Feb 2024 (T+90)
1,100 shares@ US$1.334.1% of flowCommon StockSEC:0001213900-23-088890:0
Canonical exit: 14 Feb 2024 (T+90)
1,000 shares@ US$2.1264100.0% of flowCommon StockSEC:0001213900-23-043531:0
Canonical exit: 24 Aug 2023 (T+90)
2,500 shares@ US$2.0614.5% of flowCommon StockSEC:0001213900-23-041179:0
Canonical exit: 15 Aug 2023 (T+90)
200 shares@ US$2.68151.5% of flowCommon StockSEC:0001213900-22-081513:0
Canonical exit: 19 Mar 2023 (T+90)
487 shares@ US$3.06764.3% of flowCommon StockSEC:0001213900-22-080102:0
Canonical exit: 13 Mar 2023 (T+90)
13,080 shares@ US$0.11470.022% mcap47.4% of flowCommon StockSEC:0001213900-22-033752:0
Canonical exit: 15 Sept 2022 (T+90)
5,000 shares@ US$0.15540.011% mcap22.9% of flowCommon StockSEC:0001213900-21-065395:0
Canonical exit: 10 Mar 2022 (T+90)
57,714 shares@ US$0.0020.3% of flowCommon StockSEC:0001213900-21-026675:0
Canonical exit: 15 Sept 2019 (T+90)
7,630,949 sharesCommon StockSEC:0001213900-21-026677:0
24 of 24 declarations
关于 Silo Pharma, Inc.
Silo Pharma, Inc. (Nasdaq: SILO) 是一家在美国纳斯达克股票市场上市的美国开发阶段生物制药公司。该公司最好被理解为一个早期、非多元化的生物技术平台，专注于针对未满足需求的疾病（特别是创伤后应激障碍、应激引起的焦虑症、纤维肌痛、慢性疼痛和中枢神经系统疾病）的新型疗法和药物递送系统。其投资案例主要是科学和管线驱动，而非商业驱动，价值创造与许可、临床前进展、临床去风险化和知识产权执行相关。([silopharma.com](https://silopharma.com/about/?utm_source=openai)) 该公司的历史可追溯到 2010 年，当时它最初成立，此后经历了多次公司重组。Silo 最近的公司足迹集中在佛罗里达州萨拉索塔，其主要行政办公室位于该地。公开公司文件还表明，该业务的注册地随着时间的推移而发生变化，这反映了微型生物技术公司为寻求更高效的增长和资本市场准入结构而经常经历的公司演变。([sec.gov](https://www.sec.gov/Archives/edgar/data/1514183/000121390026035576/ea0282804-10k_silo.htm?utm_source=openai)) Silo 的管线相对紧凑但概念广泛。其主要项目 SPC-15 是一种鼻内给药候选药物，旨在治疗创伤后应激障碍和应激相关焦虑症。SP-26 是一种缓释氯胺酮植入物，正在开发用于治疗纤维肌痛和慢性疼痛。临床前管线还包括 SPC-14（一种用于阿尔茨海默病的鼻内资产）和 SPU-16（一种具有多发性硬化症初步研究重点的中枢神经系统靶向肽）。这种组合使 Silo 既涉足传统疗法，也涉足受迷幻药启发或与神经学相关的开发主题。([sec.gov](https://www.sec.gov/Archives/edgar/data/1514183/000121390026035576/ea0282804-10k_silo.htm?utm_source=openai)) 从竞争角度来看，Silo Pharma 占据了医疗保健领域的一个投机性角落。它在数据包仍处于早期阶段、开发周期长且执行风险高的领域展开竞争。其以协作为导向的模式，包括大学和实验室合作，可能有助于降低发现成本，并可能支持某些资产的 505(b)(2) 式监管途径。与此同时，该公司仍然高度依赖外部资金以及推进资产以证明更高估值的能力。([silopharma.com](https://silopharma.com/about/?utm_source=openai)) 最近的公司发展一直很活跃。2025 年，Silo 宣布了一项注册直接发行，并披露了与 Hoth Therapeutics 成立潜在 50:50 合资企业以开发肥胖和代谢疾病项目的计划。2026 年，该公司宣布为基于伊博加因的疗法（针对创伤性脑损伤和相关神经精神疾病）提交临时专利申请，并强调了其创伤后应激障碍管线在政策重新关注基于迷幻药的治疗方面的战略相关性。对于投资者而言，该股票仍然是纳斯达克高度事件驱动的微型股，新闻流、融资和管线里程碑可能主导其股票故事。([nasdaq.com](https://www.nasdaq.com/press-release/silo-pharma-announces-25-million-registered-direct-offering-priced-market-under?utm_source=openai))
